The trajectory of the erectile dysfunction drug presents a intricate picture for shareholders. While the initial release generated massive returns, the end of its patent opened the floodgates to generic alternatives, https://singnalsocial.com/story6655791/viagra-and-the-pharmaceutical-industry-a-risky-bet